A Clearer View: How Tethis's New Nanotech Slides Will Capture Elusive Cells

MILAN, Italy – June 08, 2026 – In the intricate world of cellular biology, some of the most valuable players are also the most elusive. Rare cells, such as circulating tumor cells (CTCs) or specific immune cells, drift through the body in minuscule numbers, holding secrets to disease progression and treatment response. Capturing them for analysis has long been a frustrating challenge for researchers, akin to finding a single grain of black sand on a vast white beach. Today, Milan-based Tethis S.p.A. announced a new tool designed to turn this frustrating search into a routine procedure. At the EACR Conference in Budapest, the company is launching its SmartBioSurface slides, an innovation that leverages nanotechnology to make the invisible, visible.

The Nanotech Advantage: A New Surface for Science

For decades, scientists have relied on methods like cytospins to prepare slides from liquid samples. While useful, these techniques can be harsh, often leading to cell loss, morphological damage, and inconsistent results—a significant problem when every single cell counts. When studying a precious, low-cellularity sample like cerebrospinal fluid or a liquid biopsy, losing even a fraction of the material can mean the difference between a breakthrough and a dead end.

Tethis aims to solve this fundamental problem with a deceptively simple solution: a better surface. At the heart of the SmartBioSurface slide is a proprietary nanostructured titanium coating. This isn't just a smooth piece of glass; it's an engineered environment designed to mimic the body's own extracellular matrix. The result is a surface that gently and rapidly coaxes suspension cells—cells that normally float freely—to adhere within minutes, without the need for centrifugation or other disruptive forces.

The benefits, according to the company, are profound: high cell recovery even from tiny samples, a uniform distribution of cells for easier analysis, and, crucially, the preservation of cellular integrity. This claim is supported by early scientific evidence. A peer-reviewed study published in PLoS One earlier this year demonstrated that the slides could be used to isolate single cells while preserving their structure, yielding high-quality DNA suitable for a range of downstream molecular analyses. By providing a stable, clear, and uniform monolayer of cells, the technology promises to unlock the full potential of advanced imaging and single-cell workflows, giving researchers a more reliable foundation upon which to build their experiments.

Strategy Beyond the Slide

The life sciences tool market is not for the faint of heart. Tethis enters a global rare cell isolation market valued at over $2 billion and projected to more than double by 2033, driven by the relentless push for precision medicine. This space is dominated by established technologies like microfluidics and magnetic bead separation. So, how does an emerging company from Milan plan to compete?

The answer lies in its strategy, which extends far beyond selling a standalone product. Tethis is positioning SmartBioSurface not just as a better slide, but as a critical component of an integrated, standardized workflow. The slides are designed to work in concert with the company's See.d instrument, an automated system for blood sample preparation, and proprietary AI algorithms for cell identification. This platform approach is Tethis’s key differentiator, aiming to transform the often-chaotic process of liquid biopsy preparation into a standardized, reproducible, and data-rich analysis.

As CEO Holger Neecke stated, "Our goal is to provide a simple yet high-performance solution that helps scientists maximize the value of precious samples across a wide range of applications." This focus on a complete, user-friendly system rather than a single component could be a powerful advantage. By addressing the entire pre-analytical workflow, from blood draw to scannable slide, Tethis is not just selling a tool; it's selling consistency and reliability—two of the most valuable commodities in scientific research.

The Path from Research to Clinical Reality

Currently, SmartBioSurface slides are designated for "RESEARCH USE ONLY" (RUO). This label is critical; it means the product is intended for laboratory experiments and not for diagnosing diseases in patients. For many companies, the RUO market is a final destination. For Tethis, it appears to be a deliberate first step on a longer journey toward the clinic.

The company's strategic roadmap clearly points toward diagnostic applications. Tethis has already initiated clinical studies, such as a collaboration with the prestigious European Institute of Oncology, to validate the performance of its platform in detecting rare tumor and immune cells. Furthermore, company leadership has been transparent about its next major milestone: conducting the necessary performance studies to achieve CE-IVD marking, the regulatory stamp of approval for in vitro diagnostic use in Europe. This ambition is backed by significant capital, including a €15 million investment secured last year specifically to accelerate the validation and commercialization of its diagnostic platform. This deliberate, step-wise progression from research tool to validated diagnostic is a well-trodden but challenging path, and Tethis appears to be navigating it with clear intent.

Early Signals of Adoption

While the commercial launch is just happening now, early signals suggest the technology is already gaining traction within the scientific community. These early adopters and collaborators provide the strongest indication of a product's real-world potential. A recent research collaboration with Israel's Sheba Medical Center, for example, is using the Tethis platform to evaluate CTCs in rectal cancer patients, a direct application in a critical area of clinical research. This partnership with a world-leading hospital provides a powerful vote of confidence.

Furthermore, a successful proof-of-concept study with imaging company Lumito AB confirmed that the SmartBioSurface slides are compatible with other advanced technologies, demonstrating their versatility and potential to be integrated into complex, multi-modal workflows. These alliances are more than just business development; they are a form of peer review, showing that leading experts see value in the technology's ability to provide a more accurate and reproducible window into the cellular mechanisms of disease. By enabling better, more reliable sample preparation, these small glass slides may soon play a very large role in accelerating the next wave of medical discovery.